Skip to main content
OpenTrials
Completed

NCT Number: NCT03103412

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC. The relative bioavailability of tofacitinib released from TD-3504 compared to co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female between 18 to 55 years old
  • Male subjects must abstain from sexual intercourse or use a highly effective method of birth control
  • Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use a highly effective method of birth control
  • Body Mass Index (BMI) 18 to 32 kg/m2
  • Willing and able to give informed consent
  • Additional inclusion criteria apply

Inclusion criteria

for Ulcerative Colitis (UC) subjects:

  • Subject has a history of UC
  • Subject is either not taking any medication for UC or has been taking a stable dose of ulcerative colitis medications for ≥ 14 days
  • Additional inclusion criteria apply

Exclusion criteria

  • Is positive for hepatitis A, B or C, HIV or tuberculosis
  • Has clinically significant abnormalities in baseline laboratory evaluations
  • Subject has a clinically significant abnormal electrocardiogram (ECG)
  • Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to screening (or within 60 days prior to screening if investigational drug was a biologic, or is currently participating in another trial of an investigational drug (or medical device)
  • Additional exclusion criteria apply

Exclusion criteria

for Healthy Subjects:

  • Use of prescription drugs or any chronic over the counter medications within 14 days prior to clinic admission or requires continuing use during study participation, with the exception of hormonal contraceptives or hormone replacement therapy or standard daily multivitamin.
  • Additional exclusion criteria apply

Treatment and study plan

TD-3504

Drug

TD-3504

15N2-tofacitinib

Drug

15N2-tofacitinib

Placebo

Drug

Placebo

Primary outcomes

  1. Safety & tolerability of TD-3504 by assessing the number, severity, and type of adverse events

    Time frame: Day 1 through Day 8

    To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing the number, severity, and type of treatment related adverse events.

Secondary outcomes

  1. Safety & tolerability of TD-3504 by assessing treatment related changes safety laboratory values

    Time frame: Day 1 through Day 8

    To assess the safety & tolerability of TD-3504 following single escalating doses of TD-3504 co-administered with a low dose of 15N2 tofacitinib for 8 days in healthy subjects and subjects with UC by assessing treatment related changes safety laboratory values.

  2. Systemic area under the curve of TD-3504

    Time frame: Day 1 through Day 4

    To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  3. Systemic Cmax of TD-3504

    Time frame: Day 1

    To assess the systemic exposure of TD-3504 following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  4. Systemic area under the curve of tofacitinib

    Time frame: Day 1 through Day 4

    To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  5. Systemic Cmax of tofacitinib

    Time frame: Day 1

    To assess the systemic exposure of tofacitinib following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  6. Systemic area under the curve of 15N2-tofacitinib

    Time frame: Day 1 through Day 4

    To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  7. Systemic Cmax of 15N2-tofacitinib

    Time frame: Day 1

    To assess the systemic exposure of following single escalating doses of TD-3504 and co-administered 15N2-tofacitinib.

  8. Tofacitinib relative bioavailability by area under the curve comparison

    Time frame: Day 1 through Day 4

    To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.

  9. Tofacitinib relative bioavailability by Cmax comparison

    Time frame: Day 1

    To assess the relative bioavailability of tofacitinib from TD-3504 relative to 15N2-tofacitinib.

Sponsors and collaborators

Lead sponsor

Theravance Biopharma

Industry

Registry information

Official study title

Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Apr 6, 2017
Registry last updated
Jan 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.